Pritumumab
Pritumumab
Pritumumab (pronunciation: pri-tu-mu-mab) is a type of monoclonal antibody used in the treatment of certain types of cancer. It is a novel therapeutic agent that targets ectopic vimentin, a protein that is overexpressed in many types of cancer.
Etymology
The name "Pritumumab" is derived from the Latin "Pritu", meaning "first", and "mumab", a common suffix for monoclonal antibodies. This reflects its status as one of the first monoclonal antibodies developed for cancer treatment.
Usage
Pritumumab is used in the treatment of various types of cancer, including glioma, a type of brain cancer. It works by binding to ectopic vimentin, a protein that is overexpressed in many types of cancer. This binding triggers the immune system to attack and destroy the cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Ectopic vimentin: A protein that is overexpressed in many types of cancer.
- Glioma: A type of tumor that occurs in the brain and spinal cord.
See Also
External links
- Medical encyclopedia article on Pritumumab
- Wikipedia's article - Pritumumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski